PART 1: What's New in Atopic Dermatitis at AAD 2025 with Dr. Wei Jing Loo
Failed to add items
Add to Cart failed.
Add to Wish List failed.
Remove from wishlist failed.
Adding to library failed
Follow podcast failed
Unfollow podcast failed
PART 1: What's New in Atopic Dermatitis at AAD 2025 with Dr. Wei Jing Loo
-
Narrated by:
-
By:
About this listen
🎙️PART 1: From Dupilumab to Abrocitinib🩺✨
Sun-kissed Orlando sets the stage as we talk all things eczema from dupilumab to abrocitinib—after squeezing in a little Disney magic, of course.
Listen to fresh poster data on switching stubborn AD patients from dupilumab to abrocitinib and debate whether to hit hard with 200 mg or start slow at 100 mg. Rapid EASI-90 gains, itch-free nights, and a “flat-line” durability curve you’ll actually love?
Along the way you’ll hear:
- The secret sauce for counseling risk-averse AD patients who’ve already weathered methotrexate and cyclosporine.
- Why comorbid alopecia or vitiligo might tip you toward a JAK-first strategy.
🎯 Learning Objectives
- Identify the clinical profile of AD patients who fail or can’t tolerate dupilumab and may benefit from switching to a JAK inhibitor.
- Compare real-world efficacy & speed of response between abrocitinib 100 mg vs 200 mg, and craft pragmatic dose-titration plans.
- Integrate patient-reported outcomes (itch, DLQI) and comorbidity considerations into shared decision-making for advanced AD therapy.
#SkinAndJointsPodcast #AAD2025 #AtopicDermatitis #EczemaCare #JAKinhibitors #Dupilumab #Abrocitinib #DermTwitter #MedEd #Podcast 🎧
SUPPORTED BY AN IME GRANT FROM PFIZER.
About Dr Wei Jing Loo, BSc (Med), MBBS, MRCP (UK), FRCP(c)
Dermatologist | London, ON
Dr Wei Jing Loo is the owner and Medical Director of DermEffects, a cutting edge dermatology centre located in London, Ontario. Dr Loo completed medical school in 1997 with an honours degree from the University of New South Wales in Sydney, Australia. She trained in Internal Medicine and obtained membership in the Royal College of Physicians in the United Kingdom in 1999. She completed her dermatology residency training in Cambridge, United Kingdom and obtained her Certificate of Specialist Training in Dermatology in 2005. She is board certified in Canada and a fellow of the Royal College of Physicians and Surgeons of Canada. She is a member of the Canadian Dermatology Association and American Academy of Dermatology. Dr. Loo is at the forefront of the dynamic field of dermatology, serving as an associate investigator for Probity Medical Research. Dr. Loo is an Adjunct Professor at Western University in Ontario. She enjoys teaching and has published her work in many peer-reviewed journals
📻www.skinandjoints.ca
✉️info@skinandjoints.ca
📻www.skinandjoints.ca
✉️info@skinandjoints.ca